Muñiz Carmen, Teodosio Cristina, Mayado Andrea, Amaral Ana Teresa, Matarraz Sergio, Bárcena Paloma, Sanchez Maria Luz, Alvarez-Twose Iván, Diez-Campelo María, García-Montero Andrés C, Blanco Juan F, Del Cañizo Maria Consuelo, del Pino Montes Javier, Orfao Alberto
Department of Medicine and Cytometry Service (NUCLEUS), Cancer Research Center (IBMCC, USAL-CSIC), Institute for Biomedical Research of Salamanca (IBSAL), University of Salamanca (USAL), Salamanca, Spain.
Spanish Net on Aging and Frailty (RETICEF) Instituto de Salud Carlos III, Madrid, Spain.
Stem Cell Res Ther. 2015 Sep 7;6(1):169. doi: 10.1186/s13287-015-0152-8.
Mesenchymal stem cells (MSCs) are multipotent cells capable of self-renewal and multilineage differentiation. Their multipotential capacity and immunomodulatory properties have led to an increasing interest in their biological properties and therapeutic applications. Currently, the definition of MSCs relies on a combination of phenotypic, morphological and functional characteristics which are typically evaluated upon in vitro expansion, a process that may ultimately lead to modulation of the immunophenotypic, functional and/or genetic features of these cells. Therefore, at present there is great interest in providing markers and phenotypes for direct in vivo and ex vivo identification and isolation of MSCs.
Multiparameter flow cytometry immunophenotypic studies were performed on 65 bone marrow (BM) samples for characterization of CD13(high) CD105(+) CD45(-) cells. Isolation and expansion of these cells was performed in a subset of samples in parallel to the expansion of MSCs from mononuclear cells following currently established procedures. The protein expression profile of these cells was further assessed on (paired) primary and in vitro expanded BM MSCs, and their adipogenic, chondrogenic and osteogenic differentiation potential was also determined.
Our results show that the CD13(high) CD105(+) CD45(-) immunophenotype defines a minor subset of cells that are systematically present ex vivo in normal/reactive BM (n = 65) and that display immunophenotypic features, plastic adherence ability, and osteogenic, adipogenic and chondrogenic differentiation capacities fully compatible with those of MSCs. In addition, we also show that in vitro expansion of these cells modulates their immunophenotypic characteristics, including changes in the expression of markers currently used for the definition of MSCs, such as CD105, CD146 and HLA-DR.
BM MSCs can be identified ex vivo in normal/reactive BM, based on a robust CD13(high) CD105(+) and CD45(-) immunophenotypic profile. Furthermore, in vitro expansion of these cells is associated with significant changes in the immunophenotypic profile of MSCs.
间充质干细胞(MSC)是具有自我更新和多向分化能力的多能细胞。它们的多能性和免疫调节特性使其生物学特性和治疗应用越来越受到关注。目前,MSC的定义依赖于表型、形态和功能特征的组合,这些特征通常在体外扩增时进行评估,而这一过程最终可能导致这些细胞的免疫表型、功能和/或基因特征发生改变。因此,目前人们对提供用于直接体内和体外鉴定及分离MSC的标志物和表型非常感兴趣。
对65份骨髓(BM)样本进行多参数流式细胞术免疫表型研究,以鉴定CD13(高) CD105(+) CD45(-)细胞。在一部分样本中对这些细胞进行分离和扩增,同时按照目前既定的程序从单核细胞中扩增MSC。对(配对的)原代和体外扩增的BM MSC进一步评估这些细胞的蛋白表达谱,并测定它们的成脂、成软骨和成骨分化潜能。
我们的结果表明,CD13(高) CD105(+) CD45(-)免疫表型定义了一个细胞亚群,该亚群在正常/反应性BM(n = 65)的体外系统中存在,并且表现出与MSC完全兼容的免疫表型特征、贴壁能力以及成骨、成脂和成软骨分化能力。此外,我们还表明,这些细胞的体外扩增会调节其免疫表型特征,包括目前用于定义MSC的标志物(如CD105、CD146和HLA-DR)表达的变化。
基于强大的CD13(高) CD105(+)和CD45(-)免疫表型谱,可以在体外从正常/反应性BM中鉴定出BM MSC。此外,这些细胞的体外扩增与MSC免疫表型谱的显著变化相关。